Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias.
In recent years, the soluble Interleukin-2 Receptor (sIL-2R) has gained recognition as a valuable marker of in vivo activated immune functions in a variety of diseases. We studied sIL-2R levels in patients with cytomegalovirus (CMV) disease, and/or graft versus host disease (GVHD) following bone marrow transplantation (BMT). Our study included 36 patients after T-cell depleted allogenic BMT and 11 healthy controls. Mean sIL-2R serum levels were significantly higher after BMT than before (1273 u/ml vs. 629 u/ml, respectively, p < 0.007). In the patients who developed CMV disease, with or without GVHD, mean sIL-2R levels increased significantly (2866 u/ml p < 0.004); there was a drop after recovery (1949 u/ml), but not a return to pre-CMV onset levels. Similar elevated sIL-2R levels were found in patients during CMV disease only, GVHD only, or both. In patients who developed GVHD, sIL-2R levels were positively correlated with the severity of GVHD (Pearson's correlation coefficient .8322, p < 0.003). We conclude that sIL-2R may serve as a valuable nonspecific marker for the presence of CMV disease and severity of GVHD following T-lymphocyte depleted BMT.
Engelhard
D
D
Department of Pediatrics, Hadassah University Hospital, Jerusalem, Israel.
Nagler
A
A
Singer
R
R
Barak
V
V
D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000097:blood; D016026:Bone Marrow Transplantation / Q000276:immunology* / Q000502:physiology; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000097:blood* / Q000175:diagnosis; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood* / Q000175:diagnosis; D006650:Histocompatibility Testing; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008212:Lymphocyte Depletion; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000276:immunology / Q000628:therapy; D008297:Male; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D012016:Reference Values; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
D015415:Biomarkers; D015375:Receptors, Interleukin-2